In 2021, two covalent inhibitors of KRAS-G12C protein (hereafter referred to as G12Ci), sotorasib (AMG 510) [15] and adagrasib (MRTX849) [16], were clinically approved by the U.S. Food and Drug Administration and the European Medicines Agency to treat patients with advanced NSCLC carrying the KRAS-G12C mutation. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.